Accordingly, immune suppression may increase the risk of tumor growth, relapse and metastasis [44-46] Thus, we speculated that the number of CD3+, CD4+ cells, CD4/CD8 ratio, and circulating CD19+ lymphocytes could be used to assess prostate cancer progress and prognosis. This evidence concerns the gene CD8A and neoplasm.